Tyr839
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr839  -  OSMR (human)

Site Information
LTkPNyLyLLPTEkN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 475364
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 10 ) , mutation of modification site ( 6 , 9 )
Disease tissue studied:
gastric cancer ( 2 , 4 , 7 ) , gastric carcinoma ( 4 ) , liver cancer ( 9 ) , lung cancer ( 8 , 10 ) , non-small cell lung cancer ( 8 , 10 ) , neuroblastoma ( 1 , 5 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on OSMR:
phosphorylation ( 6 )

References 

1

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

2

Rikova K (2012) CST Curation Set: 16137; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

3

Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

4

Possemato A (2011) CST Curation Set: 11925; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Guo A (2010) CST Curation Set: 10553; Year: 2010; Biosample/Treatment: cell line, SMS-KCN-A/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

6

Hintzen C, et al. (2008) Box 2 region of the oncostatin M receptor determines specificity for recruitment of Janus kinases and STAT5 activation. J Biol Chem 283, 19465-77
18430728   Curated Info

7

Guo A (2006) CST Curation Set: 1929; Year: 2006; Biosample/Treatment: cell line, SNU-5/-; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Rikova K (2006) CST Curation Set: 1703; Year: 2006; Biosample/Treatment: cell line, LCLC-103H/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Stross C, et al. (2006) Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism. J Biol Chem 281, 8458-68
16459330   Curated Info

10

Rikova K (2006) CST Curation Set: 1105; Year: 2006; Biosample/Treatment: cell line, NCI-H596/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info